Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
7077043 | Bioresource Technology | 2014 | 8 Pages |
Abstract
Shikimate is a key intermediate for the synthesis of the neuraminidase inhibitors. Microbial production of shikimate and related derivatives has the benefit of cost reduction when compared to traditional methods. In this study, an overproducing shikimate Escherichia coli strain was developed by rationally engineering certain metabolic pathways. To achieve this, the shikimate pathway was blocked by deletion of shikimate kinases and quinic acid/shikimate dehydrogenase. EIICBglc protein involved in the phosphotransferase system, and acetic acid pathway were also removed to increase the amount of available phosphoenolpyruvate and decrease byproduct formation, respectively. Thereafter, three critical enzymes of mutated 3-deoxy-D-arabinoheptulosonate-7-phosphate (DAHP) synthase (encoded by aroGfbr), PEP synthase (encoded by ppsA), and transketolase A (encoded by tktA) were modularly overexpressed and the resulting recombinant strain produced 1207Â mg/L shikimate in shake flask cultures. Using the fed-batch process, 14.6Â g/L shikimate with a yield of 0.29Â g/g glucose was generated in a 7-L bioreactor.
Related Topics
Physical Sciences and Engineering
Chemical Engineering
Process Chemistry and Technology
Authors
Xianzhong Chen, Mingming Li, Li Zhou, Wei Shen, Govender Algasan, You Fan, Zhengxiang Wang,